Argatroban as an Alternative Anticoagulant in the Case of Heparin-Induced Thrombocytopenia after Pediatric Cardiac Surgery
| Autor: | Martina Heschl, Gabriele Leitner-Peneder, Anna Hofer, Jens Meier |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.drug_class medicine.medical_treatment Anticoagulant Heparin medicine.disease Thrombosis Argatroban Surgery Fontan procedure Venous thrombosis Direct thrombin inhibitor Heparin-induced thrombocytopenia Medicine cardiovascular diseases Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Clinical & Experimental Cardiology. 6 |
| ISSN: | 2155-9880 |
| DOI: | 10.4172/2155-9880.1000408 |
| Popis: | Heparin-induced thrombocytopenia (HIT) represents a major challenge in patients following the fenestrated Fontan procedure. These patients are prone to thrombosis within the Fontan tunnel due to the low blood flow velocity. The communication between the Fontan tunnel and the common atrium may enable systemic embolization and can cause a stroke. Effective on-going anticoagulation is necessary. Given the high risk of arterial and venous thrombosis with HIT, alternate anticoagulation management is essential as soon as HIT is suspected. We are reporting on two patients who developed HIT antibodies and thrombocytopenia after exposure to heparin during a Fontan procedure. Both the PF4 enzyme-linked immunosorbent assay (LIFECODES® PF4 IgG assay) and the heparin-induced platelet aggregation test (HIPA, Institut fur Immunologie und Transfusionsmedizin, Greifswald, Germany) were positive. The children were treated with argatroban (Argatra®, Mitsubishi Pharma), a direct thrombin inhibitor. In only one patient was HIT associated with thrombosis within the Fontan tunnel. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|